Curapath has partnered with Nacalai Tesque to expand access to its portfolio of next-generation polymers and PEG-free shielding lipids for advanced drug delivery applications in Japan. This collaboration strengthens Curapath’s global presence and enables local availability of high-quality excipients for researchers and biopharma companies working on non-viral delivery technologies.
Through this agreement, Nacalai Tesque will distribute Curapath’s proprietary excipients, including PSar- and PGA-diol-based shielding lipids, polymer materials, and active targeting lipids. These technologies are designed to support lipid nanoparticle (LNP) development and other delivery platforms used in gene therapy, RNA therapeutics, DNA vaccines, and biologics.
Curapath’s portfolio includes PEG-free shielding lipids developed as alternatives to conventional PEGylated systems, as well as polymers such as polyamino acids and cationic polymers used in gene delivery and transfection. The agreement also covers ready-to-use active targeting shielding lipids, designed to enable LNP delivery to extrahepatic tissues and support next-generation targeting strategies. All materials are developed and manufactured at Curapath’s facilities in Valencia, Spain.
By leveraging Nacalai Tesque’s established distribution network, Curapath ensures local access to its advanced excipients in Japan, accelerating research and development in nucleic acid therapeutics and advanced drug delivery systems.
“Through this collaboration, we aim to make our materials more accessible to Japanese researchers working on next-generation therapies,” said Victor de la Rosa, commercial product manager at Curapath. “Japan represents an important market for innovation in drug delivery, and this partnership allows us to better support that ecosystem.”
“We have been exploring innovative solutions that can deliver new value to our customer base. In this process, we identified strong potential in Curapath’s advanced lipid nanoparticle (LNP) technology and its high-quality related products,” said Tomoyuki Yoneda, Head of Procurement & Logistics at Nacalai Tesque. “Through this partnership, we aim to provide more comprehensive solutions to researchers in the field of nucleic acid therapeutics in Japan”
Nacalai Tesque brings extensive experience in supplying high-quality reagents and research tools to academic institutions and pharmaceutical companies across Japan, providing a strong platform for the distribution of advanced excipients.
This partnership reflects a shared commitment to advancing non-viral drug delivery and enabling the development of next-generation therapeutic modalities.
About Curapath
Curapath is a science-driven CDMO specializing in the design, development, and GMP manufacturing of advanced drug delivery systems. The company supports biopharma partners from early R&D through commercial production, with a strong focus on non-viral gene delivery using polymer and lipid-based nanoparticles.
To learn more about Curapath you can contact us here: https://curapath.com/
About Nacalai Tesque
Nacalai Tesque is a leading Japanese supplier of high-quality reagents and life science solutions, supporting research and innovation across academia and the pharmaceutical industry. With a strong presence in Japan, Nacalai provides scientists with reliable tools to advance discovery and therapeutic development.
To learn more about Nacalai visit: https://www.nacalai.com/global/brand/#slide1
